• Shanghai Henlius annual report for year ended Dec. 31, 2025 highlighted third straight year of profitability, with overseas product revenue doubling year on year.
• Global footprint expanded to 10 marketed products across more than 60 markets, with cumulative patients treated topping 1 million.
• US momentum strengthened with three new product clearances in 2025, including HLX11 as first pertuzumab biosimilar launched in US.
• Europe ramped with three product clearances in EU and UK, with serplulimab launch extended to 12 countries.
• Pipeline focus shifted toward late-stage innovation, with serplulimab advancing in perioperative gastric cancer, HLX22 moving through global phase 3, HLX43 posting early efficacy signals across solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260424-12121638), on April 24, 2026, and is solely responsible for the information contained therein.